Doxorubicin treatment increases metastasis of prostate tumor (R3327-MatLyLu).
Doxorubicin (Dx) effects on metastatic spreading of prostate cancer were investigated using a rat metastatic tumor (R3327-MatLyLu). Intravenous injection of monodispersed tumor cells resulted in tumor nodule formation in the lungs. A simultaneous bolus injection of Dx (3.2 mg/Kg) caused a significant decrease in lung colony formation and growth. However, Dx administered during the course of spontaneous metastasis, or as adjuvant chemotherapy 24 hours before surgical removal of primary tumor, caused a significant increase in metastasis to the lungs. It is concluded that an intravenous doxorubicin bolus injection does not provide an antimetastatic effect, but increases metastatic spreading of prostate tumor.
Geldof
A A
AA
Department of Endocrinology, Academisch Ziekenhuis Vrije Universiteit, Amsterdam, The Netherlands.
Rao
B R
BR
D000818:Animals; D002460:Cell Line; D004317:Doxorubicin / Q000494:pharmacology*; D008175:Lung Neoplasms / Q000473:pathology / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D009362:Neoplasm Metastasis / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000473:pathology*; D051381:Rats
D004317:Doxorubicin